Search

Karyopharm Therapeutics Inc

Closed

SectorHealthcare

1.91 -72.64

Overview

Share price change

24h

Current

Min

6.53

Max

7.03

Key metrics

By Trading Economics

Income

80M

-22M

Sales

987K

35M

EPS

-1.24

Profit margin

-63.857

Employees

228

EBITDA

8M

-9.8M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

-19.12% downside

Market Stats

By TradingEconomics

Market Cap

-38M

161M

Previous open

74.55

Previous close

1.91

News Sentiment

By Acuity

50%

50%

162 / 340 Ranking in Healthcare

Karyopharm Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 lip 2026, 23:41 UTC

Social Media
Event
News

Karyopharm Therapeutics shares fell sharply after its Phase 3 trial for selinexor failed to meet key endpoints, leading to a shift in focus away from endometrial cancer.

29 lip 2026, 19:27 UTC

Macro Event

Karyopharm Therapeutics shares are lower as investor anxiety rises following the Federal Reserve's decision to maintain interest rates amid global uncertainties.

27 lip 2026, 19:07 UTC

Karyopharm Therapeutics Inc shares are lower during Monday's trading session, reflecting ongoing weakness and broader market trends amid declining crude oil prices.

24 lip 2026, 19:42 UTC

Karyopharm Therapeutics Inc. shares are higher during Friday's session, continuing a notable advance since Thursday, despite broader market challenges.

23 lip 2026, 09:01 UTC

Karyopharm Therapeutics Inc shares are higher in pre-market trading, continuing an upward trend since Wednesday, despite recent volatility and no specific news.

22 lip 2026, 18:41 UTC

Social Media

Karyopharm Therapeutics shares are declining amid market caution and rising crude oil prices. RBC Capital reaffirmed its Outperform rating with a $16 price target.

21 lip 2026, 20:12 UTC

Karyopharm Therapeutics shares are lower in after-market hours, with no specific news driving the decline despite positive sentiment in U.S. markets.

20 lip 2026, 23:01 UTC

News

Karyopharm Therapeutics shares fell in after-market hours following the announcement of a leadership cash retention program aimed at key executives.

Peer Comparison

Price change

Karyopharm Therapeutics Inc Forecast

Price Target

By TipRanks

-19.12% downside

12 Months Forecast

Average 5.67 USD  -19.12%

High 7 USD

Low 3 USD

Based on 5 Wall Street analysts offering 12 month price targets forKaryopharm Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

2

Buy

3

Hold

0

Sell

Sentiment

By Acuity

162 / 340 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

help-icon Live chat